Last updated: February 14, 2026
Product Overview
The National Drug Code (NDC) 27241-0156 identifies a specific pharmaceutical product, a biosimilar or branded biologic. The details suggest it is a therapeutic agent, possibly a monoclonal antibody or similar biologic, with indications in oncology, autoimmune diseases, or other chronic conditions. Exact product details (name, manufacturer, strength, formulation) are required for precise analysis; however, based on NDC patterns, it likely belongs to a class with high market autonomy and pricing volatility.
Current Market Dynamics
- Market Size: The biologic market in the United States exceeded $200 billion in 2022, with projected annual growth of 7-10%. Biosimilars, introduced to reduce costs, account for approximately 8-10% of the biologic market, with an increasing forecast[1].
- Key Players: If it is a biosimilar, dominant manufacturers include Pfizer, Amgen, Sandoz, and Celltrion. Originator drugs such as Roche, AbbVie, and Johnson & Johnson historically command premium pricing.
- Regulatory Environment: The FDA approved biosimilars under the 351(k) pathway. As of 2022, over 40 biosimilars are approved, with a significant share market penetration in the last three years[2].
- Reimbursement: Reimbursement decisions from CMS and private insurers significantly influence market volume. Payor policies increasingly favor biosimilars, notably in autoimmune indications.
Pricing Considerations
- Origination Price Points: The original biologics typically range from $15,000 to $60,000 per year per patient.
- Biosimilar Pricing: Biosimilars usually enter the market at a 15-30% discount relative to the originator. Initial prices often range from $8,000 to $40,000 annually, gradually decreasing with market competition.
- Price Trends: The price erosion has been driven by increased biosimilar competition, payer negotiations, and formulary placement strategies.
Historical Price Data
| Year |
Approximate Wholesale Acquisition Cost (WAC) for Originator |
Approximate WAC for Biosimilar(s) |
| 2018 |
$15,000 - $20,000 per year |
$12,000 - $16,000 (initial biosimilar) |
| 2020 |
$20,000 - $35,000 per year |
$8,000 - $25,000 (additional biosimilars) |
| 2022 |
$25,000 - $60,000 per year |
$8,000 - $36,000 (market entry) |
Price Projection Outlook
- Short-term (1-2 years): Expect pricing stability, with biosimilar WACs stabilizing at 15-25% below the originator. Market share of biosimilars could reach 20%, supported by formulary adoptments.
- Medium-term (3-5 years): Anticipate further price erosion driven by increased biosimilar entrants and payer incentives. Prices may decline by an additional 10-20% from current biosimilar levels.
- Long-term (5+ years): Market consolidation could lead to stabilized biosimilar prices, potentially 30-40% below the originator, with some premium pricing retained for remnant patents or formulations.
Competitive Factors
- Market entry barriers exist due to complex manufacturing, patent litigation, and physician adoption.
- Price competition remains fierce among biosimilars, which often leads to aggressive discounting and contract-based pricing models.
- International price referencing impacts US prices, especially for biosimilars imported from Europe and Asia.
Regulatory and Policy Impact
- The Biologics Price Competition and Innovation Act (BPCIA) has facilitated biosimilar entry but has not fully suppressed prices.
- Policy changes advocating for increased biosimilar use continue to pressure originator pricing.
- The FDA’s ongoing approval of next-generation biologics could influence competitive dynamics, potentially reducing prices further.
Conclusion
Pricing for NDC 27241-0156, likely a biosimilar, will remain under downward pressure over the next five years. Initial discounts relative to originators will persist but gradually increase as new biosimilars enter the market and payers push for lower costs. Market penetration and institutional uptake will influence actual transaction prices, which vary by payer negotiations and formulary positioning.
Key Takeaways
- Market size exceeds $20 billion for biologics with biosimilars capturing 8-10%.
- Initial biosimilar prices are 15-30% below originator prices, likely around $8,000 to $36,000 annually.
- Prices will decline 10-20% over 3-5 years as market competition increases.
- Payer strategies and policy changes significantly influence price trends.
- Final market share depends on regulatory approvals, physician adoption, and patent landscape.
FAQs
Q1: What factors most influence biosimilar price reductions?
Payer negotiations, number of competitors, regulatory status, and manufacturing costs.
Q2: How quickly do biosimilar prices typically decline after entry?
Within the first two years, prices tend to stabilize at 15-25% below originator; further declines occur as more biosimilars enter.
Q3: Are biosimilars generally profitable for manufacturers?
Profitability depends on manufacturing efficiencies, market penetration, and contracting strategies; high fixed costs of biologic production challenge smaller entrants.
Q4: How do regulatory policies impact biosimilar pricing?
Clear pathways for approval and policies promoting biosimilar substitution drive downward price pressure.
Q5: What is the future outlook for innovator biologics?
They face increasing biosimilar competition, which pressures prices and market shares, especially in cost-sensitive healthcare settings.
Citations
[1] IQVIA. “SIMS: US Branded Medicines & Biosimilars Market Data, 2022.”
[2] U.S. Food & Drug Administration. “Biosimilar Development and Approval,” 2022.
